NurExone and NanoPass Collaborate on Exosome Delivery for Eye and Skin Applications

NurExone Biologic Inc. and NanoPass Technologies Ltd. have entered into a Memorandum of Understanding to evaluate the integration of NanoPass's MicronJet platform with NurExone's exosome formulations for eye and skin applications. The companies plan to conduct preclinical studies to assess the feasibility of using NanoPass's platform for suprachoroidal delivery in ophthalmology and intradermal delivery in dermatology and aesthetics. The collaboration aims to support the development of an integrated exosome-and-delivery product for professional use and standardization.